Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Alvespimycin · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | Patients whose last dose is \> 21 days prior to first dose of Trastuzumab on study. First infusion: 90 mins for 4 mg/kg loading dose of trastuzumab followed by 60 min infusion of alvespimycin. Subsequent infusions weekly 30 mins for 2 mg/kg trastuzumab followed by 60 min infusion of alvespimycin Patients whose last dose is \< 21 days prior to first dose of Trastuzumab on study. All infusions: 30 mins for 2 mg/kg trastuzumab followed by 60 min infusion of alvespimycin |
| Arm 2 | EXPERIMENTAL | Patients whose last dose is \> 21 days prior to first dose of Trastuzumab on study. First infusion: 90 mins for 4 mg/kg loading dose of trastuzumab followed by 60 min infusion of paclitaxel and 60 min of infusion of alvespimycin. Subsequent infusions weekly 30 mins for 2 mg/kg trastuzumab followed by 60 min infusion of paclitaxel and 60 min infusion of alvespimycin Patients whose last dose is \< 21 days prior to first dose of Trastuzumab on study. All infusions: 30 mins for 2 mg/kg trastuzumab followed by 60 min infusion of paclitaxel and 60 min infusion of alvespimycin. Subsequent infusions weekly 30 mins for 2 mg/kg trastuzumab followed by 60 min infusion of paclitaxel and 60 min infusion of alvespimycin |
| Name | Type | Description |
|---|---|---|
| Alvespimycin | DRUG | Solution, IV, 60-100 mg/m2, weekly until disease progression or DLT |
| Trastuzumab | DRUG | Solution, IV, 2-4 mg/kg, weekly until disease progression or DLT |
| Paclitaxel | DRUG | Solution, IV, 60-90 mg/m2, weekly until disease progression or DLT |
Inclusion Criteria: * KPS performance status \>= 70% * Schedule A: all patients must have a histologically confirmed solid tumor malignancy. Schedule B: patients must have metastatic breast cancer with Her2 amplification by FISH or 3+ Her2 overexpression by immunohistochemistry ("IHC"). Patients ar...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
Alvespimycin is an investigational small molecule being studied for the treatment of solid tumors, including HER2 positive metastatic breast cancer. It was evaluated in a Phase 1 clinical trial in patients with advanced solid tumor malignancies or HER2 positive metastatic breast cancer who had previously failed trastuzumab therapy.
Alvespimycin is being developed by Bristol-Myers Squibb Company, traded on the New York Stock Exchange under the ticker BMY. The company sponsored a Phase 1 clinical trial of the drug in combination with trastuzumab, with or without paclitaxel, in patients with advanced solid tumors.
Alvespimycin is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The single Phase 1 trial of Alvespimycin has been completed, and the drug is no longer in active clinical trials.
Alvespimycin was studied in one completed Phase 1 clinical trial, identified as NCT00803556. This trial evaluated the combination of intravenous Alvespimycin, trastuzumab, with or without paclitaxel, in patients with advanced solid tumor malignancies or HER2 positive metastatic breast cancer who had previously failed trastuzumab therapy.
Yes, Alvespimycin is also known as KOS-1022. The clinical trial NCT00803556 refers to the drug as Alvespimycin (KOS-1022), indicating that these names are used interchangeably for the same investigational compound.